Eli Lilly (LLY): Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. TSLA
3. WBD
4. NVDA
5. AMD
6. USO
7. AMC
8. META
9. MSFT
10. AMZN

Go back to Eli Lilly (LLY): Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1159.15 +6.22 (0.54%)
Previous Close $1152.93    52 Week High $88.16 
Open $1144.50    52 Week Low $67.88 
Day High $1168.44    P/E 268.32 
Day Low $1134.41    EPS $4.32 
Volume 775,962